Intus Biosciences

Executive Summary

Intus Biosciences, founded in 2021 and headquartered in San Diego, is developing the Titan-1™ platform, which integrates long-read amplicon sequencing with AI and machine learning to deliver strain-level resolution of the microbiome. This technology aims to overcome limitations of short-read sequencing and traditional metagenomics, enabling precise identification of microbial strains for applications in precision diagnostics, biomarker discovery, and therapeutic development. The company's approach has the potential to transform microbiome science by providing actionable insights that can guide clinical decision-making and drug development. As a private early-stage company, Intus is well-positioned to capitalize on the growing interest in microbiome-based diagnostics and therapeutics. The platform's ability to deliver high-resolution microbial data could attract partnerships with pharmaceutical and diagnostic companies seeking to incorporate microbiome insights into their pipelines. While the company has not yet disclosed funding or revenue, its innovative technology and strong scientific foundation suggest significant upside potential. Conviction is moderate given the early stage and competitive landscape, but the differentiated platform warrants attention.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Announcement70% success
• 2026-2027Key Partnership with Pharma or Diagnostic Company65% success
• 2027Commercial or Research Launch of Titan-1 Platform55% success